Introduction
============

Wound healing is a complex and dynamic process that is essential for tissue homeostasis. In normal adult wound healing, disruption to skin integrity triggers a series of coordinated events typically classified into three overlapping phases: The inflammatory phase entails recruitment of inflammatory cells into the wound; the proliferative phase involves the formation of granulation tissue and re-epithelialisation; and during the remodelling phase, the wound contracts and the scar matures ([@b1-etm-0-0-3263]). Chronic wounds may be defined as those that fail to progress through the reparative processes required to restore tissue integrity within three months ([@b2-etm-0-0-3263]). This inability to heal is associated with cellular and molecular abnormalities within the wound bed and often involves chronic inflammation ([@b3-etm-0-0-3263]). Chronic wounds represent a significant burden to the UK National Health Service, with an estimated cost of \>£1 billion per year ([@b4-etm-0-0-3263]). One of the major challenges for clinicians is recognising which wounds will heal and which will become chronic; therefore, methods for early diagnosis of the non-healing wound are important for earlier and more aggressive intervention.

In 1988, a novel growth factor for precursor B cells was identified and designated lymphopoietin-1 ([@b5-etm-0-0-3263]). Now more commonly known as interleukin (IL)-7, its functional significance and therapeutic potential continue to be investigated. As a pleiotropic cytokine, IL-7 is involved in early B and T cell development ([@b5-etm-0-0-3263]--[@b10-etm-0-0-3263]), growth, maintenance and differentiation of thymocytes ([@b11-etm-0-0-3263]--[@b14-etm-0-0-3263]) and peripheral T-cell homeostasis ([@b15-etm-0-0-3263]--[@b17-etm-0-0-3263]). IL-7 expression has been detected in numerous types of tissue, including bone marrow ([@b5-etm-0-0-3263]), thymus gland ([@b9-etm-0-0-3263],[@b12-etm-0-0-3263]), liver, kidney, spleen ([@b8-etm-0-0-3263]), intestine ([@b18-etm-0-0-3263],[@b19-etm-0-0-3263]) and skin ([@b6-etm-0-0-3263],[@b19-etm-0-0-3263],[@b20-etm-0-0-3263]).

The IL-7 receptor (IL-7R) complex is a heterodimer of transmembrane proteins, the IL-7 specific α chain (also known as CD127) and the common γ chain (CD132) ([@b21-etm-0-0-3263],[@b22-etm-0-0-3263]). Neither component is unique to IL-7 signalling, with the α chain also being utilised by thymic stromal lymphopoietin ([@b23-etm-0-0-3263],[@b24-etm-0-0-3263]) and the common γ chain by other members of the interleukin family, including IL-2, IL-4, IL-9 and IL-15 ([@b25-etm-0-0-3263]--[@b28-etm-0-0-3263]). Although it is predominantly expressed by cells of the lymphoid lineage, IL-7R has also been detected in human endothelial cell lines ([@b29-etm-0-0-3263]) and several cancer cell lines, including lung, central nervous system, renal, colon, breast and skin cancer, as well haematological malignancies ([@b30-etm-0-0-3263]). It also exists in a soluble form that is capable of binding IL-7 in solution ([@b21-etm-0-0-3263]). IL-7R activation by IL-7 binding leads to dose-dependent phosphorylation of Janus kinase (JAK)-1 and JAK-3 and subsequent phosphorylation of signal transducer and activator of transcription 5, which then translocates to the nucleus to induce gene transcription ([@b31-etm-0-0-3263],[@b32-etm-0-0-3263]), as reviewed by Mazzucchelli and Durum ([@b33-etm-0-0-3263]). IL-7 has also been demonstrated to activate the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt) signalling pathway in murine and human thymocytes which is known to influence cell survival ([@b32-etm-0-0-3263],[@b34-etm-0-0-3263],[@b35-etm-0-0-3263]); however, the exact nature of this signalling pathway is not fully understood.

Although its role in immunological development has been known for some time, studies with IL-7 transgenic mice revealed its potential to act as an oncogene *in vivo* and promote the malignant transformation of B and T cells ([@b36-etm-0-0-3263]). IL-7 has been demonstrated to affect cell growth and survival in certain haematological malignancies, including acute lymphoblastic leukaemia ([@b37-etm-0-0-3263]--[@b39-etm-0-0-3263]), cutaneous T cell lymphoma ([@b20-etm-0-0-3263],[@b40-etm-0-0-3263],[@b41-etm-0-0-3263]), Hodgkin\'s disease ([@b42-etm-0-0-3263]), acute myeloid leukaemia ([@b43-etm-0-0-3263]) and chronic lymphocytic leukaemia ([@b39-etm-0-0-3263],[@b43-etm-0-0-3263],[@b44-etm-0-0-3263]). IL-7 mRNA has also been identified in numerous solid organ tumours, including Warthin\'s tumour of the parotid gland ([@b45-etm-0-0-3263]), head and neck squamous cell carcinomas ([@b46-etm-0-0-3263]), renal cell carcinoma ([@b47-etm-0-0-3263]), oesophageal carcinoma ([@b48-etm-0-0-3263]), colorectal carcinoma ([@b49-etm-0-0-3263]) and breast carcinoma ([@b19-etm-0-0-3263]). The exact role of IL-7 in these tumours is not fully understood, however it is thought to affect lymphocytes ([@b49-etm-0-0-3263]); for instance, in cutaneous T-cell lymphoma, IL-7 has been shown to support the growth of malignant T-cells in the skin ([@b21-etm-0-0-3263]). Increased IL-7 expression in breast cancer is associated with a higher tumour grade and poorer prognostic outcome ([@b19-etm-0-0-3263]). This may be due to the effects of aberrant IL-7 expression on the development, growth and differentiation of breast cancer ([@b19-etm-0-0-3263]), the ability of IL-7 to act as a potent growth factor for breast cancer and endothelial cells ([@b50-etm-0-0-3263]) and/or the ability of IL-7 to stimulate lymphangiogenesis in breast cancer cells *in vitro* and in a mouse model ([@b51-etm-0-0-3263],[@b52-etm-0-0-3263]). These findings are concordant with analyses conducted on non-small cell lung cancer (NSCLC), in which tumours with high IL-7 expression were more advanced and more likely to have metastasised to lymph nodes, possibly due to stimulation of lymphangiogenesis ([@b53-etm-0-0-3263]). Postoperative survival rates were shorter in patients with higher levels of IL-7/IL-7R expression ([@b54-etm-0-0-3263]). Furthermore, the expression levels of IL-7 have been reported to correlate with tumour stage and the presence of lymph node metastases ([@b54-etm-0-0-3263]). *In vitro* studies have demonstrated that IL-7 stimulates lung cancer cell proliferation and increases cyclin D1 mRNA and protein expression, higher levels of which correlate with reduced survival rates in patients with NSCLC ([@b55-etm-0-0-3263]).

During the study of IL-7 within the fields of haematology and immunology, it was noted that murine and human normal keratinocytes express IL-7 mRNA and protein *in vitro* ([@b6-etm-0-0-3263],[@b20-etm-0-0-3263],[@b56-etm-0-0-3263]). It appears that one function of IL-7 in skin is to promote the survival and growth of epidermal T-cells ([@b56-etm-0-0-3263],[@b57-etm-0-0-3263]). These results prompted further investigation of the role of IL-7 in inflammatory cutaneous disease, and its involvement has been suggested in atopic dermatitis ([@b6-etm-0-0-3263]), bullous pemphigoid ([@b58-etm-0-0-3263]) and cutaneous T-cell lymphoma ([@b20-etm-0-0-3263]). To the best of our knowledge, no reports have been published regarding a correlation between IL-7 and wound healing. Parallels have been made between the pathophysiological parameters observed in cancer biology and wound healing ([@b59-etm-0-0-3263],[@b60-etm-0-0-3263]). Given the involvement of IL-7 in inflammation and immune responses, its role in tumour development and progression and its expression by human keratinocytes, the present study investigated the effect of IL-7 on wound healing.

Materials and methods
=====================

### Wound tissue cohort

Information regarding the wound tissue cohort and collection has been previously described ([@b61-etm-0-0-3263]). Briefly, the tissue cohort consisted of 71 chronic venous leg ulcer wound edge biopsies. The tissue samples were collected from patients attending the University of Wales wound healing clinic, following ethical approval by the South East Wales Research Ethics Committee (reference no. 09/WSE02/59). Informed written consent was provided by all patients. Samples were obtained from 71 patients between 2010 and 2013, 43% of whom were male and 57% were female. The mean age of these patients was 72.2 years, with a sample range of 34--99 years old. Over a 12 week follow-up of the subjects, 20 chronic wounds displayed substantial healing following conventional compression therapy and these samples were thus defined as 'healing' chronic wounds. The remaining chronic wounds that remained static or were enlarged over the 12-week period of conventional therapy were termed 'non-healing' chronic wounds for the purpose of this study. Biopsies were initially stored at −80°C prior to immersion in liquid nitrogen. The tissue biopsies were sectioned using a CM1950 cryostat (Leica Microsystems Ltd., Milton Keynes, UK) at a size of 7 µm for immunohistochemical analysis and 20 µm for use in RNA extraction and generation of cDNA for reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis, where multiple tissue sections were combined and homogenised using a hand held homogeniser (Cole-Parmer Instrument Co., Ltd., London, UK) in ice-cold total RNA isolation reagent (TRI) reagent^®^ (Sigma-Aldrich Co., Ltd., Irvine, UK).

### Reagents, cell lines and culture conditions

The HaCaT human keratinocyte cell line was purchased from the German Cancer Research Institute (Heidelberg, Germany). The cells were grown and maintained at 37°C, 5% CO~2~ and 95% humidity in Dulbecco\'s modified Eagle\'s medium (Sigma-Aldrich Co., Ltd.) supplemented with 10% foetal calf serum (Sigma-Aldrich Co., Ltd.) and 100X antibiotic antimycotic solution (Sigma-Aldrich Co., Ltd.; final concentration 50,000 units penicillin, 50 mg streptomycin and 125 µg amphotericin B per 500 ml). Recombinant human IL-7 (rhIL-7) was purchased from R&D Systems (Abingdon, UK). The neuronal Wiskott-Aldrich syndrome protein (N-WASp) inhibitor Wiskostatin and the Akt inhibitor were purchased from Merck Millipore (Calbiochem; Watford, UK).

### RNA extraction and reverse transcription

Total RNA was extracted from the homogenised sections of wound tissue and human keratinocytes using TRI reagent as described in the manufacturer\'s protocol (Sigma-Aldrich Co., Ltd.). Once extracted, the RNA was quantified using a spectrophotometer (WPA UV 1101; Biotech Photometer, Cambridge, UK) and RNA quantity was standardised to 250 ng prior to reverse transcription using an iScript cDNA synthesis kit according to the manufacturer\'s instructions (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK). Subsequently, cDNA was diluted 1:16 with nuclease-free water (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and used for RT-qPCR.

### Immunohistochemical staining

Frozen wound tissue sections were fixed in dried acetone (Thermo Fisher Scientific, Inc.) for 15 min, air dried for 15 min and then hydrated in Tris-buffered saline (TBS). The tissue sections were incubated in wash buffer containing 10% horse serum (Sigma-Aldrich Co., Ltd.) for 1 h prior to incubation with monoclonal mouse anti-IL-7 primary antibody (cat. no. MAB207; R&D Systems) diluted at a 1:100 concentration (2 µg/ml final concentration) for 1 h at room temperature. Subsequently, the tissue sections were washed four times in TBS buffer prior to identification of primary antibody binding using a Vectastain Elite ABC (Universal) avidin-biotin peroxidase kit in accordance with the manufacturers protocol (Vector Laboratories, Ltd., Peterborough, UK). Visualisation of the staining intensity was obtained through the addition of 3,3′-diaminobenzidine to the tissue sections. Finally, tissue sections were counterstained with haematoxylin (Vector Laboratories, Ltd.), washed thoroughly in tap water and subjected to dehydration through a graded series (50, 70, 90, 100, 100%) of absolute ethanol (Thermo Fisher Scientific, Inc.), prior to being cleared in xylene and mounted in DPX mounting medium (Merck Millipore). Staining intensity and localisation were visualised under a Leica DM1000 LED microscope (Leica Microsystems Ltd.). Negative controls were prepared using only the secondary universal antibody contained within the Vectastain Elite ABC (Universal) kit, in accordance with the manufacturer\'s protocol.

### RT-qPCR

IL-7 expression levels were examined within the wound tissue cohort using RT-qPCR as previously described ([@b61-etm-0-0-3263],[@b62-etm-0-0-3263]). Briefly, the primer pairs were designed incorporating a complementary sequence (termed the Z sequence) to the Amplifluor uniprimer probe (InterGen, New York, NY, USA) into the reverse primer. RT-qPCR was undertaken using an IQ5 system (Bio-Rad Laboratories, Ltd.) and transcript copy numbers were calculated based on the quantification of a defined internal standard run on the same plate. Sample/standard cDNA was added to iQ supermix (Bio-Rad Laboratories Ltd.), target specific forward primer (10 pM), reverse primer containing the Z sequence (1 pM) and the Amplifluor uniprimer probe (10 pM). The reaction conditions were as follows: 15 min at 95°C followed by 80 cycles of 95°C for 15 sec, 55°C for 60 sec and 72°C for 20 sec. Sample transcript number was subsequently normalised based on sample total expression levels of the GAPDH housekeeping gene. Full primer details are presented in [Table I](#tI-etm-0-0-3263){ref-type="table"}.

### In vitro growth assay

An *in vitro* cell growth assay was used to examine the impact of IL-7 on HaCaT cell growth. HaCaT cells were seeded at a density of 3×10^3^ cells/well into triplicate 96-well plates. Plates were treated, where required, with the indicated concentration of rhIL-7 (0, 1, 10 and 100 ng/ml) and incubated overnight for 3 or 5 days. At each incubation point the appropriate 96-well plate was fixed in 4% formaldehyde (v/v) and stained with 0.5% (w/v) crystal violet (Sigma-Aldrich Co., Ltd.). Plates were subsequently treated with 10% acetic acid (v/v) and placed in an ELx800 spectrophotometer plate reader (Bio-Tek Instruments Inc., Winooski, VT, USA).

### Electric cell-substrate impedance sensing (ECIS) detection of cell migration

Cell migration was detected using an ECIS Zθ system (Applied Biophysics Inc., Troy, NY, USA) as described previously ([@b63-etm-0-0-3263]). Briefly, cells were added to 96-well electrode arrays (96W1E) in identical numbers (80,000 cells/well) and allowed to form a fully confluent monolayer. Following confluence, the cells were wounded through the application of 6 V for 30 sec/well, generating a consistently sized 'wound' in the monolayer. The change in resistance was measured in each well as the cells migrated back to recolonise the electrode. This process was completed in the presence of varying concentrations of rhIL-7 (0, 1, 10 and 100 ng/ml) and the rate of change of resistance was taken as an indication of cellular migration. Subsequently, 20 ng/ml of rhIL-7 was used in conjunction with a range of small molecule inhibitors to determine potential interactions between these signalling pathways on IL-7-regulated migration.

### Statistical analysis

The SigmaPlot 11 statistical software package (Systat Software Inc., London, UK) was used to identify statistically significant differences between experimental groups. The data were analysed using parametric two sample, two-tailed t-test or analysis of variance (ANOVA), or non-parametric Mann-Whitney or ANOVA on RANKS depending on normality. All *in vitro* assays were repeated a minimum of three times. Data is presented as mean ± standard deviation or median ± interquartile range. P\<0.05 was considered to indicate a statistically significant result.

Results
=======

### IL-7 expression levels in healing and non-healing chronic wounds

RT-qPCR was used to compare the mRNA levels of IL-7 expression in the healing and non-healing wounds ([Fig. 1](#f1-etm-0-0-3263){ref-type="fig"}). IL-7 expression levels were higher in healing chronic wounds (median expression, 0.196) compared with non-healing chronic wounds (median expression, 0.00469), although this difference was not statistically significant (P=0.229).

Immunohistochemical analysis was performed on 26 representative chronic wound tissue samples. A total of 13 tissue samples were defined as non-healing (wound size had increased or remained the same), and the remaining 13 as healing (wounds had either completely healed or there was a decrease in size). In line with the RT-qPCR findings, IL-7 expression was generally enhanced in healing wound tissue and the majority of healing wounds (8/13) showed cytoplasmic IL-7 expression in all the layers of the epidermis. By contrast, the majority of the non-healing wounds did not show IL-7 expression (9/13), and in cases where faint staining was observed, it was localised in the basal layer ([Fig. 2](#f2-etm-0-0-3263){ref-type="fig"}).

### IL-7 enhances keratinocyte migration in vitro

To determine the effect of IL-7 on keratinocyte migration *in vitro*, HaCaT cells were treated with various concentrations of rhIL-7 and cell migration was analysed using the ECIS system. Following electrical wounding, HaCaT cells treated with rhIL-7 migrated at a faster rate compared with untreated cells ([Fig. 3A](#f3-etm-0-0-3263){ref-type="fig"}) and there appeared to be a concentration-dependent gradient, with the maximum effect observed following treatment with 100 ng/ml rhIL-7. To further investigate this effect, cell migration was examined in the presence of IL-7 and numerous small molecule signalling pathway inhibitors. Concordant with the original observations, treatment of HaCaT cells with IL-7 (20 ng/ml) induced an increase in cell migration rates compared with the untreated controls. However, marked effects on cell migration were observed when rhIL-7 was combined with an Akt inhibitor ([Fig. 3B](#f3-etm-0-0-3263){ref-type="fig"}) or N-WASp inhibitor ([Fig. 3C](#f3-etm-0-0-3263){ref-type="fig"}). In both cases, the combination of rhIL-7 with the inhibitor induced an evident increase in cellular migration rate.

### IL-7 does not affect keratinocyte growth in vitro

To determine the effect of IL-7 on keratinocyte growth, HaCaT cells were treated with various concentrations of rhIL-7 and cell growth was analysed over a 3-day or 5-day incubation period. No difference in cell growth was observed between the untreated HaCaT controls and the cells treated with various concentrations of rhIL-7 at day 3 or 5, and there were no statistically significant differences observed between the groups at days 3 or 5 (P\>0.05; [Fig. 4](#f4-etm-0-0-3263){ref-type="fig"}).

Discussion
==========

Wound healing is a complex process that requires interaction between numerous cytokines and growth factors ([@b1-etm-0-0-3263]). A greater understanding of these factors and interactions may provide an insight into possible treatments of chronic wounds. Therefore, the present study investigated the presence of IL-7 in healing and non-healing wounds, and its effect on keratinocytes *in vitro*.

IL-7 is a pleomorphic cytokine expressed in normal human keratinocytes ([@b6-etm-0-0-3263]), where it has been previously shown to support epidermal T-cell growth and survival ([@b56-etm-0-0-3263],[@b57-etm-0-0-3263]). It has an important role in immunological development, including involvement in early B- and T-cell development ([@b5-etm-0-0-3263]--[@b10-etm-0-0-3263]) and peripheral T-cell homeostasis ([@b15-etm-0-0-3263]--[@b17-etm-0-0-3263]). IL-7 may also act as an oncogene, stimulating malignant transformation, and cell growth and survival in haematological cancers ([@b36-etm-0-0-3263]--[@b43-etm-0-0-3263]).

The results of the present study demonstrated that IL-7 expression was higher in healing chronic wounds compared with non-healing chronic wounds, although the difference was not statistically significant. This was supported by immunohistochemical analysis, which also demonstrated that IL-7 expression was enhanced in healing chronic wounds, being expressed in all layers of the epidermis. To investigate the potential underlying causes for this, the effects of rhIL-7 on human keratinocytes were analysed *in vitro*. Although rhIL-7 treatment led to faster keratinocyte migration, it did not affect the cell growth. Therefore, if IL-7 is affecting wound healing, it appears that the mechanism underlying its effects may occur via enhanced keratinocyte migration. Given that previous studies have demonstrated the role of IL-7 as a growth factor for epidermal T-cell growth and survival ([@b56-etm-0-0-3263],[@b57-etm-0-0-3263]), it is possible that IL-7 may be involved in the inflammatory phase of wound healing. However, a study of mRNA expression in human dermal wounds demonstrated that IL-7 mRNA expression levels initially decreased then increased in the middle and late phases of wound healing ([@b64-etm-0-0-3263]). These results are concordant with the data of the present study, which indicated that rhIL-7 enhanced keratinocyte migration, a process that occurs during re-epithelialisation. IL-7 was shown to be a growth factor for endothelial cells in breast cancer studies ([@b51-etm-0-0-3263],[@b52-etm-0-0-3263]); therefore, it may influence neoangiogenesis and re-vascularisation, another essential element of wound healing that occurs following the initial inflammatory phase. Since IL-7 supports cancer cell proliferation and growth ([@b20-etm-0-0-3263],[@b50-etm-0-0-3263],[@b54-etm-0-0-3263]), it was initially hypothesised that it may enhance keratinocyte growth *in vitro*. However, no significant impact of rhIL-7 on HaCaT cell growth was observed following *in vitro* assays, despite the addition of high concentrations of rhIL-7.

Akt is a serine/threonine kinase involved in numerous cellular signalling pathways. It is an important mediator of numerous functions initiated by growth factor receptors that activate PI3K ([@b65-etm-0-0-3263]). Akt is oncogenic and contributes to the malignant behaviour of cells, promoting cell survival, enhancing tumour cell invasion, and stimulating motility ([@b66-etm-0-0-3263]). IL-7 has been shown to activate the PI3K/Akt signalling pathway, promoting the survival of certain immune and cancer cells ([@b32-etm-0-0-3263],[@b34-etm-0-0-3263],[@b35-etm-0-0-3263],[@b67-etm-0-0-3263]). In order to evaluate the potential signalling pathways involved in the pro-migratory effect of rhIL-7 on HaCaT cells, two small inhibitors (Akt and N-WASp) were used to target the possible downstream signalling pathways of IL-7. Since previous studies suggested that Akt stimulates cell motility, a reasonable hypothesis appears to be that inhibiting Akt may negate the pro-migratory effect of IL-7. However, the opposite was shown, since a marked increase in cell migration was observed upon addition of the Akt inhibitor. A previous study demonstrated that IL-24 inhibited keratinocyte migration *in vitro* via an Akt-dependent signalling pathway, where addition of an Akt inhibitor reversed the inhibition of migration caused by IL-24 ([@b61-etm-0-0-3263]). However, the results of the current study suggested that inhibition of Akt, through small molecular inhibitors, had a pro-migratory effect on HaCaT cells when combined with rhIL-7 treatment. The precise mechanism underlying this phenomenon is not fully known.

Wiskott-Aldrich syndrome (WAS) is a primary immunodeficiency disorder, in which lymphocytes exhibit cytoskeletal abnormalities and a reduced response to proliferative stimuli ([@b68-etm-0-0-3263]). The WAS gene encodes a prolene-rich protein, termed WASp. Neural WASp (N-WASp) is a 65 kDa protein with a 50% homology to WASp that was first identified in the bovine brain ([@b69-etm-0-0-3263]). Unlike WASp, which is only expressed in haematopoietic cells, N-WASp is ubiquitous ([@b68-etm-0-0-3263]). N-WASp is required for stimulation of actin polymerization, a process necessary for cell movement and division ([@b70-etm-0-0-3263]). It has also been shown to stabilise intracellular adherens junctions, which maintain the endothelial barrier ([@b71-etm-0-0-3263]). The results of the present study demonstrated that inhibition of N-WASp caused a marked increase in the cellular migration rate with the addition of rhIL-7 *in vitro*. This suggested that N-WASp may have been acting to prevent migration, possibly replicating its activity in endothelial cells.

In conclusion, as chronic wounds continue to pose a significant health problem, investigations to uncover the complex processes required for prompt wound healing are ongoing. The results of the present study demonstrated that IL-7 may have a role in keratinocyte migration and may be differentially expressed between healing and non-healing chronic wounds. Further studies are required to fully establish this association and the significance of IL-7 in chronic wound healing and in the wound healing process as a whole, using different clinical cohorts with acute and chronic wound tissues. The data also suggested a potential association between IL-7 and N-WASp and Akt signalling, although additional investigation isrequired to fully understand this association and its significance to clinical wound healing.
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![Reverse transcription-quantitative polymerase chain reaction analysis of IL-7 expression levels in clinical samples. Median IL-7 expression levels were increased in healing chronic wounds compared with non-healing chronic wounds, although no significant differences were observed. Descriptive data is presented in the table. IL-7, interleukin-7; IQR, interquartile range.](etm-12-01-0033-g00){#f1-etm-0-0-3263}

![Immunohistochemical staining analysis of IL-7 expression in clinical tissue samples. Staining profiles demonstrated an increase in IL-7 expression in chronic-healing tissue sections compared with chronic non-healing tissue sections. Representative images are shown at ×40, ×100, ×200 and ×400 magnifications. Negative controls are representative of tissue sections undergoing staining with only secondary antibody. IL-7, interleukin-7.](etm-12-01-0033-g01){#f2-etm-0-0-3263}

![Electric cell substrate impedance sensing analysis of cellular migration. (A) Following electrical wounding rhIL-7 was demonstrated to have a dose-dependant effect on cellular migration. (B) Addition of the Akt inhibitor or the (C) N-WASp inhibitor wiskostatin in combination with rhIL-7 substantially enhanced the pro-migrational impact compared with rhIL-7 alone. Representative images shown. rhIL-7, recombinant human interleukin-7; Akt, protein kinase B.](etm-12-01-0033-g02){#f3-etm-0-0-3263}

![Cell growth rate analysis. No significant effects on growth potential were observed in the HaCaT keratinocyte cell line following the addition of rhIL-7 at 1, 10 or 100 ng/ml concentrations. Data are presented as mean ± standard error. rhIL-7, recombinant human interleukin-7.](etm-12-01-0033-g03){#f4-etm-0-0-3263}

###### 

Primers used in the present study.

  Primer   Forward (5′-3′)            Reverse (3′-5′)
  -------- -------------------------- ----------------------------------------
  IL-7     ATTGTGATATTGAAGGTAAAGATG   *ACTGAACCTGACCGTACA*GCACGGAATAAA
  GAPDH    AAGGTCATCCATGACAACTT       *ACTGAACCTGACCGTACA*GCCATCCACAGTCTTCTG

*ACTGAACCTGACCGTACA* denotes the Z sequence. IL, interleukin.
